Progesterone Receptor Negative Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02954874Pembrolizumab in Treating Patients With Triple-Negative Breast CancerTreatment